Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473711 | 1.00 | KMT2A (0.41) | KMT2AMEN1EPHX2LMNAALDH1A1 | |
| SCHEMBL22473663 | 1.00 | KMT2A (0.41) | KMT2AMEN1EPHX2LMNAALDH1A1 | |
| SCHEMBL22473808 | 0.89 | EPHX2 (0.45) | KMT2AEPHX2LMNAALDH1A1GLP1R | |
| SCHEMBL22473699 | 0.89 | EPHX2 (0.45) | KMT2AEPHX2LMNAALDH1A1GLP1R | |
| SCHEMBL22473791 | 0.87 | ALDH1A1 (0.43) | KMT2AMEN1EPHX2ALDH1A1GLP1R | |
| SCHEMBL22473740 | 0.87 | MEN1 (0.42) | KMT2AMEN1EPHX2ALDH1A1GLP1R | |
| SCHEMBL19249122 | 0.87 | EPHX2 (0.43) | KMT2AEPHX2LMNAALDH1A1GLP1R | |
| SCHEMBL24673317 | 0.86 | TSHR (0.40) | KMT2AMEN1EPHX2ALDH1A1GLP1R | |
| SCHEMBL22526077 | 0.86 | TSHR (0.40) | KMT2AMEN1EPHX2ALDH1A1GLP1R | |
| SCHEMBL24672702 | 0.86 | TSHR (0.40) | KMT2AMEN1EPHX2ALDH1A1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787443-B2 | RAF-degrading conjugate compounds | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787443-B2 | RAF-degrading conjugate compounds | BRAF, RAF1, ARAF | KMT2A 1376/4885MEN1 2085/4885EPHX2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.